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Background: Hepatocellular carcinoma (HCC) is one of the most common cancers in the world,and the
identification of biomarkers for the early detection is a relevant target. The purpose of the study is to discover
specific low molecular weight (LMW) serum peptidome biomarkers and establish a diagnostic pattern for HCC.
Methods: We undertook this pilot study using a combined application of magnetic beads with Matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) technique and ClinPro Tools v2.2 to detect
32 patients with HCC, 16 patients with chronic hepatitis (CH), 16 patients with liver cirrhosis (LC) and 16 healthy
volunteers.
Results: The results showed 49, 33 and 37 differential peptide peaks respectively appeared in HCC, LC and CH
groups. A Supervised Neural Network (SNN) algorithm was used to set up the classification model. Eleven of the
identified peaks at m/z 5247.62, 7637.05, 1450.87, 4054.21, 1073.37, 3883.64, 5064.37, 4644.96, 5805.51, 1866.47 and
6579.6 were used to construct the peptides patterns. According to the model, we could clearly distinguish between
HCC patients and healthy controls as well as between LC or CH patients and healthy controls.
Conclusions: The study demonstrated that a combined application of magnetic beads with MALDI-TOF MB
technique was suitable for identification of potential serum biomarkers for HCC and it is a promising way to
establish a diagnostic pattern.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1503629821958720.
Keywords: Hepatocellular carcinoma, Chronic hepatitis, Liver cirrhosis, Magnetic beads, Matri-assisted laser
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Primary liver cancer (PLC) is one of the most common
digestive cancers. HCC accounts for 90% of PLC [1].
HCC is the fifth most common human cancer, with
approximately 750 000 new cases occurring worldwide
every year [2]. HCC ranks the third in the annual global
cancer mortality rates [3] and the average time from the
discovery of symptoms to death is 6–20 months [1,4-6].
In China HCC is one of the leading causes of mortality
and morbidity [7]. Surgery, chemotherapy and radiation* Correspondence: newzhuqing1972@yahoo.com
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reproduction in any medium, provided the ortreatments can be effective therapy, which depending on
the stages of cancer and other factors. The high case-
fatality rate can be partly attributed to lack of methods
to early diagnosis. Early diagnosis and treatment is an ef-
fective way to improve patient survival. Serum markers
are thought to be simple and accurate tools for HCC
diagnosis; However, no ideal biomarker has been found
so far. Although alpha fetoprotein (AFP) is the most widely
used serum biomarker for HCC diagnosis, its sensitivity
(39-64%) and specificity (76-91%) are not optimal [8-10]. In
addition, patients with CH or LC may also show elevated
AFP levels [11,12]. Furthermore, liver biopsy is an inva-
sive procedure and not suitable for screening of HCC.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Dataset of serum samples and their donors
Group Sample size Gender Mean age Age range
HCC 32 27 M/5 F 52.72 26-70
LC 16 11 M/5 F 54.31 40-69
CH 16 11 M/5 F 54.06 42-73
Healthy control 16 11 M/5 F 54.69 43-66
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sitive and specific methods for the early diagnosis of HCC.
Proteomics is currently considered the most powerful
tool for the global evaluation of protein expression [13]
since protein deficiency is considered common in cancer
patients. Peptides in human serum may have a correlation
with the physiologic and pathologic processes [14].
Low molecular weight (LMW) proteins, particularly on
peptides smaller than 20 KDa, are expected to yield
useful biomarkers for early diagnosis of cancers [15].
Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS) can detect peptides
with low molecular weights [16,17] and is considered to
be a powerful proteomic technology for serum peptide
profiling. Magnetic beads (MB) based purification ap-
proaches has been developed to capture large amounts
of LMW peptides and proteins in biological samples,
which are suitable for the next MS analyses [18]. Combined
with MALDI-TOF MS technology, MB is more precise,
rapid and robust than the traditional two-dimensional
(2-D) gel electrophoresis. MB-based platform for proteomic
profiling highlights the high sensitivity and reproducibility.
This method has been applied to identify biomarkers for
diseases such as esophageal carcinoma [19], multiple mye-
loma [20], lung cancer [21] and breast cancer [22].
In the study, MALDI-TOF MS analysis coupled with
MB-WCX were used to detect 32 patients with HCC,
16 patients with CH, 16 patients with LC and 16 healthy
volunteers. We aimed to investigate LMW serum
protein/peptide biomarkers for HCC and ultimately




The Autoflex III MALDI-TOF mass spectrometer, α-cyano-
hydroxy cinnamic acid (HCCA), MB-WCX kit and peptide
calibration standard were purchased from Bruker Daltonics
(Germany).
Patients and sample collection
The study was approved by the Ethics Committee and the
Human Research Review Committee of Xi’an Jiaotong
University. A total of 80 serum samples were collected,
of which 32 were collected from HCC patients, 16 from
patients with CH, 16 from patients with LC and 16 from
healthy volunteers as healthy control. The dataset of
serum samples and their donors are listed in Table 1,
while the patients’ information about diagnostics, age,
sex and potential cause are listed in Additional file 1.
These blood samples were collected in the first Affiliated
Hospital of Xi’an Jiaotong University (China), from October
2011 to September 2012. All the HCC patients had been
recently diagnosed and pathologically confirmed beforethey were treated with chemotherapy or radio therapy
or surgery. The healthy subjects were those who were
hepatitis B surface antigen (HBsAg) negative, and had
no evidence for malignant tumor, no chronic diseases,
and no dysfunction of vital organs. All blood samples
were drawn while the patients and healthy controls were
seated and non-fasting. The samples were collected in
vacuum tubes, allowed to clot at room temperature for
30 min, and then centrifuged at 3,000 rpm for 5 min.
The serum samples were distributed into 300 μL aliquots
each and stored at −80°C until analysis.Sample purification and MALDI-TOF MS analysis
Magnetic beads-based weak cation exchange chroma-
tography (ClinProtTM purification reagent sets of Bruker
Daltonics) was used to extract peptides/proteins from
the serum samples following the manufacturer’s standard
protocol. 10 μl of MB-WCX binding solution and 10 μl
of WCX-beads were mixed in a 0.5 ml centrifuge tube.
After the mix was thoroughly combined, 5 μl serum
sample was added and mixed up and down. Then cen-
trifuge tubes were placed in a magnetic bead separator
(MBS) and agitated three times. The beads were col-
lected from the wall of the tubes in the MBS 1 min
later. Remove the supernatant carefully by using a pip-
ette and add 100 μl MB-WCX wash buffer to the tubes,
which were agitated back and forth in the MBS ten
times. The beads were collected from the wall of the
tubes, and supernatant was removed carefully. After
two washes, 5 μl of MB-WCX elution buffer was added
to disperse beads in tubes by pipetting up and down
ten times. The beads were collected on wall of tubes
for 2 min and the clear supernate were transferred into
fresh tubes. 5 ul MB-WCX stabilization solution was
added to the fresh tubes and mixed intensively by pipetting
up and down. The eluate was then ready for spotting onto
MALDI-TOF MS targets and measurement.
To prepare the MALDI target, 1 μL of a mixture
containing 10 μL 0.3 g/L α-cyano-4-hydroxy cinnamic
acid (HCCA) in 2:1 ethanol/acetone (volume/volume)
and 1 μL of the eluate was spotted onto the MALDI
AnchorChip TM (Bruker Daltonics, Germany) sample
target platform (384 spots) and then the target was air-
dried (cocrystallization).
Figure 1 Representative protein spectrum (1,000-10,000 Da) obtained from 4 group patients. (A) One sample of hepatocellular carcinoma.
(B) One sample of liver cirrhosis. (C) One sample of chronic hepatitis. (D) One sample of healthy control.
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A linear Autoflex III MALDI-TOF mass spectrometer
(Bruker Daltonics, Germany) was used with the followingsettings: ion source 1, 20.00 kV; ion source 2, 18.40 kV;
lens, 7.50 kV; and pulsed ion extraction, 120 ns. Ionization
was achieved via irradiation at the laser frequency of
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to 800 Dalton (Da) was used. The mass spectra were
recorded in a linear positive mode. Mass calibration was
performed using the calibration mixture of the peptides
and proteins in the mass range of 1–10 kDa. Three
MALDI preparations (MALDI spots) were measured for
every MB fraction. For every MALDI spot, 450–550 spectra
were quantified (30 laser shots at 15 to 18 different spot
positions). The spectra were recorded automatically using
the Autoflex Analysis software for the fuzzy-controlled ad-
justment of the critical instrument settings to generate raw
data with optimized quality.
Data processing with ClinPro tools software
Data analyses were performed using Flex analysis version
3.0 and ClinPro Tools 2.2 (Bruker Daltonics, Germany).
ClinPro Tools version 2.2 that uses a standard data prep-
aration workflow including spectra pretreatment, peak
picking and peak calculation operation, was employed to
recognize peptide patterns. For statistical analysis, a SNN
algorithm as implemented in this software suite was used
to identify statistically significant differences in protein
peaks among the groups analyzed. The protein fingerprint
data were analyzed by ClinPro Tools 2.2. Comparisons
between HCC, chronic hepatitis, liver cirrhosis and healthy
controls were performed with the Wilcoxon test. Statistical
significance was assumed when P value was < 0.001.
Results
Serum LMW protein profile identification
MALDI-TOF MS combined with MB-WCX were used
in the study to detect LMW protein profile spectra. A
total of 80 serum samples from 32 HCC patients, 16 LC
patients, 16 CH patients and 16 healthy controls were
analyzed (Table 1) and the representative protein profile
spectrum of each group was reported as in Figure 1.Figure 2 Comparison of the average expression levels at 12 m/z peakComparison of mass spectra between HCC, CH, LC and
controls
We analyzed the LMW protein spectra of the three patient
groups and healthy controls using a combined application
of MB-WCX and MALDI-TOF MS within the mass range
from 1 kDa to 10 kDa. Comparing three patient groups
with the healthy controls, the study respectively detected
72, 62 and 58 m/z peaks in HCC, LC and CH groups; 49,
33 and 37 of them were significant (p < 0.001) when HCC,
LC and CH groups compared with the healthy controls.
When detection across all these groups was performed,
there were 64 significant peaks. The average expressions of
12 selected peaks were exhibited as shown in Figure 2.
Analysis of the LMW protein biomarkers and
establishment of a diagnostic model for HCC
The protein samples were classified and a diagnostic
model was established by using the SNN algorithm in
ClinPro Tools software 2.2 to analyze all the detected
peaks. The model comprised 11 potential biomarkers
(m/z: 5247.62, 7637.05, 1450.87, 4054.21, 1073.37, 3883.64,
5064.37, 4644.96, 5805.51, 1866.47, 6579.6). The peaks at
m/z 5247.62, 7637.05, 1073.37, 5064.37, 5805.51 and 6579.6
were up-regulated in the HCC group, while the peaks
at m/z 1450.87, 4054.21, 3883.64, 4644.96 and 1866.47
were down-regulated in the HCC group. A combination
of these 11 peaks could clearly distinguish between HCC
patients and healthy controls as well as between LC or
CH patients and healthy controls.
Discussion
Hepatic tumor has different cell types, such as hepa-
tocellular carcinoma, cholangiocarcinoma, bile duct
cystadenocarcinoma, combined hepatocellular and
cholangiocarcinoma, hepatoblastoma, undifferentiated
carcinoma, hepatic angiomyolipoma, while differents (p < 0.001) between 4 groups.
Ying et al. Diagnostic Pathology 2013, 8:130 Page 5 of 6
http://www.diagnosticpathology.org/content/8/1/130biomarkers have been developed and investigated for
diagnosis, tumor progression, and prognosis of them
[23-26]. It is also well recognized that biomarkers which
may play important roles in physiologic and pathologic
processes are important for diagnosis, prognosis, and pre-
diction of HCC. Human serum contains LMW protein/
peptides, which could be used as biomarker candidates,
such as fibrinogen α-chain fibrinogen alpha, albumin and
apolipoprotein A1 [27,28].
Compared to genomic approaches, proteomic analysis
has the advantage of detecting co-translational and post-
translational modifications of proteins which may have
important biological functions [29]. MS is one of the most
important techniques in proteomic analysis. MALDI-TOF
MS is widely used in proteomics biomarker research due
to its high sensitivity and high quality in analysis of pep-
tides, proteins and large organic molecules [27-29].
HCC is one of the most common cancers in the world.
Although AFP is a widely used serological marker for
detection of HCC, its sensitivity and specificity are not
optimal and it may also increase in patients with acute
and chronic viral hepatitis, liver cirrhosis, and toxic in-
jury [8,9]. Therefore, use of AFP in the screening of early
HCC is challenged and a new method for HCC early
diagnosis is badly needed.
At present, serum or plasma proteomic analysis has been
widely used to compare tumor patients with healthy con-
trols. This technique can also be applied to HCC serum or
plasma markers research. Looi KS et al. (2008) applied a
proteomic approach (two-dimension gel electrophoresis
and liquid chromatography-tandem mass spectrometry) to
immune-screen sera from patients with HCC and pre-HCC
conditions such as liver cirrhosis and chronic hepatitis
as well as sera from normal individuals, and identified
28 HCC-associated tumor antigens, such as heat shock
protein 60 (HSP60) and heat shock protein 70 (HSP70)
[30]. Mas VR et al. (2009) used Thermo linear ion-trap
mass spectrometer (LTQ) coupled with a high performance
liquid chromatography electrospray ionization tandem
mass spectrometry (HPLC-ESI-MS/MS) and SEQUEST
database search algorithms for peptide sequence identifica-
tion. They found that 18 proteins from HCC patients
showed significant changes compared with proteins from
patients with HCV-cirrhosis and early HCV-HCC [31].
In the study, serum samples were divided into four
groups (HCC, LC, CH and normal controls). MB-WCX
was used for purification of LMW proteins/peptides in
these serum samples. Peptides profile spectra were detected
by MALDI-TOF MS and analyzed by ClinProt Tools soft-
ware 2.2. We found 49 (HCC group), 33 (LC group) and 37
(CH group) peaks were significantly different from those in
healthy controls (p < 0.001). All these peak differences may
be associated with pathologic processes, specific immunity
response or some risk factors, and may become potentialbiomarkers in early diagnosis. In addition, when comparing
HCC patients with healthy controls, Liu T et al. (2011)
reported 9 significant discrimination peaks at m/z
2862.79, 8862.77, 8931.95, 3935.62, 8141.78, 5248.47,
3955.45, 7765.78 and 1944.91 [32], which are close to
2863.11, 8867.91, 8931.25, 3935.27, 8138.19, 5247.62,
3955.8, 7763.84 and 1945.42 detected in the present
study. In fact, a single biomarker has an inherent specificity
and sensitivity that can not be improved, but multiple
biomarkers can be combined to achieve improved clinical
performance. In the study a diagnostic model generated by
SNN algorithm analysis comprised 11 potential biomarkers
(m/z: 5247.62, 7637.05, 1450.87, 4054.21, 1073.37, 3883.64,
5064.37, 4644.96, 5805.51, 1866.47 and 6579.6). Using this
established diagnostic model, HCC, LC and CH patients
could be distinguished from healthy controls; However, the
HCC, LC or CH group could not be accurately identified
using the model probably due to the small number of the
patients enrolled in the study. Therefore, a large number of
patients should be enrolled in the further study to establish
a diagnostic model that is effective enough to distinguish
among the three diseases.
Now, we are making investigation on these 11 m/z
peaks that are co-expressed in hepatocellular carcinoma
and other liver-related diseases in order to identity and
characterize these biomarkers. In future research, we will
validate them by western blot or ELISA technology and
try to find a correlation with histopathology findings and
cancer staging. Furthermore, we will reveal the biological
roles of these proteins/peptides in the pathogenesis and
processes of HCC.
Conclusions
The study confirmed that the combined application of mag-
netic beads, MALDI-TOF MS technique and ClinPro Tools
2.2 are suitable for LMW serum proteomic analysis and it
is a promising way to establish a diagnostic pattern. A limi-
tation of the study is the small number of patients enrolled
in the study. A study with a large patient cohort is needed
to generate more objective and conclusive results. With a
large number of patients, different HCC stages and impact
factors could be analyzed and more objective evaluation
could be made on ClinProt technology applied in HCC.
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and potential cause.
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